We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Hikma Pharmaceuticals (HIK) Ordinary GBP 0.10

Sell:2,462.00p Buy:2,464.00p 0 Change: No change
FTSE 100:0.25%
Market closed Prices as at close on 25 October 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Change: No change
Market closed Prices as at close on 25 October 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Change: No change
Market closed Prices as at close on 25 October 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 300 products in different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

Contact details

1 New Burlington Place
United Kingdom
+44 (020) 73992760

Important dates

Future events
There are no future events available.
Past events
Interim dividend payment date 20 September 2021 20/09/21
Interim ex-dividend date 19 August 2021 19/08/21
Interim results 06 August 2021 06/08/21
Trading Announcement 30 April 2021 30/04/21
Final dividend payment date 26 April 2021 26/04/21
AGM 23 April 2021 23/04/21
Final ex-dividend date 18 March 2021 18/03/21
Annual report 17 March 2021 17/03/21
Final results 25 February 2021 25/02/21
Trading Announcement 05 November 2020 05/11/20

General stock information

Market cap:
£5.69 billion
Shares in issue:
231.48 million
Pharmaceuticals & Biotechnology
London Stock Exchange
Sterling pence
FTSE 100,FTSE 350,FTSE All Share

Key personnel

  • Said Darwazah
    Executive Chairman of the Board
  • Sigurdur Olafsson
    Chief Executive Officer, Executive Director
  • Mazen Darwazah
    Executive Vice Chairman of the Board, President of MENA
  • Khalid Nabilsi
    Chief Financial Officer
  • Brian Hoffman
    President, US Generics Division
  • Riad Mishlawi
    President - Injectables
  • Bassam Wael Rushdi Kanaan
    Executive Vice President - Corporate Development and M&A
  • Majda Labadi
    Executive Vice President - Organisational Development
  • Henriette Nielsen
    Executive Vice President - Business Operations
  • Susan Ringdal
    Executive Vice President - Strategic Planning and Global Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.